Placebo News and Research

RSS
Montreal Heart Institute and Cerenis commence CER-001 Phase 2 study in acute coronary syndrome

Montreal Heart Institute and Cerenis commence CER-001 Phase 2 study in acute coronary syndrome

16 Mar 2011
AstraZeneca commences NKTR-118 Phase III clinical programme for opioid-induced constipation

AstraZeneca commences NKTR-118 Phase III clinical programme for opioid-induced constipation

16 Mar 2011
Unigene initiates oral PTH Phase 2 study in postmenopausal women with osteoporosis

Unigene initiates oral PTH Phase 2 study in postmenopausal women with osteoporosis

16 Mar 2011
iTherX commences ITX-5061 Phase 1b study in patients with HCV

iTherX commences ITX-5061 Phase 1b study in patients with HCV

16 Mar 2011
Incyte’s ruxolitinib COMFORT-II Phase III trial in MF meets primary endpoint

Incyte’s ruxolitinib COMFORT-II Phase III trial in MF meets primary endpoint

15 Mar 2011
Oxford Biomedica’s TroVax(R) TRIST Phase III study results to be published in Cancer Immunology, Immunotherapy

Oxford Biomedica’s TroVax(R) TRIST Phase III study results to be published in Cancer Immunology, Immunotherapy

15 Mar 2011
Cerenis commences CER-001 Phase 2 CHI-SQUARE study in patients with ACS

Cerenis commences CER-001 Phase 2 CHI-SQUARE study in patients with ACS

15 Mar 2011
Positive top-line results from IPX066 Phase III study in patients with PD

Positive top-line results from IPX066 Phase III study in patients with PD

15 Mar 2011
Euthymics Bioscience initiates EB-1010 phase 2b/3a TRIADE clinical trial for major depressive disorder

Euthymics Bioscience initiates EB-1010 phase 2b/3a TRIADE clinical trial for major depressive disorder

14 Mar 2011
KAI initiates enrollment in KAI-4169 Phase 2 study for secondary hyperparathyroidism

KAI initiates enrollment in KAI-4169 Phase 2 study for secondary hyperparathyroidism

14 Mar 2011
Transcept initiates enrollment in TO-2061 Phase 2 study for treatment resistant obsessive compulsive disorder

Transcept initiates enrollment in TO-2061 Phase 2 study for treatment resistant obsessive compulsive disorder

14 Mar 2011
Omthera commences dosing in pivotal Epanova Phase III EVOLVE trial in patients with very high triglycerides

Omthera commences dosing in pivotal Epanova Phase III EVOLVE trial in patients with very high triglycerides

14 Mar 2011
BioInvent commences BI-204 phase II study in patients with acute coronary syndrome

BioInvent commences BI-204 phase II study in patients with acute coronary syndrome

14 Mar 2011
Tamoxifen against breast cancer can save lives and reduce medical costs

Tamoxifen against breast cancer can save lives and reduce medical costs

14 Mar 2011
Women with DCIS have excellent overall prognosis despite treatment

Women with DCIS have excellent overall prognosis despite treatment

14 Mar 2011
Otelixizumab Phase 3 DEFEND-1 study in new-onset autoimmune type 1 diabetes does not meet primary endpoint

Otelixizumab Phase 3 DEFEND-1 study in new-onset autoimmune type 1 diabetes does not meet primary endpoint

11 Mar 2011
Supernus SPN-812 Phase IIa U.S. clinical trial in ADHD meets primary endpoints

Supernus SPN-812 Phase IIa U.S. clinical trial in ADHD meets primary endpoints

11 Mar 2011
BioSpecifics 2010 net loss decreases to $1.5 million

BioSpecifics 2010 net loss decreases to $1.5 million

11 Mar 2011
Arena fourth quarter net loss decreases to $28.2 million

Arena fourth quarter net loss decreases to $28.2 million

11 Mar 2011
Inhibitex fourth quarter net loss increases to $7.0 million

Inhibitex fourth quarter net loss increases to $7.0 million

11 Mar 2011

Terms

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

Provide Feedback